



MEDICARE FORM

Eylea® (aflibercept) Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:

FAX: 1-844-268-7263

PHONE: 1-866-503-0857 (TTY: 711)

For other lines of business:

Please use other form.

Note: Eylea is non-preferred. The preferred products are bevacizumab (Avastin) first followed by Byooviz. Avastin (C9257) and bevacizumab biosimilars do not require precertification for ophthalmic use.

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy, Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:		Last Name:		DOB:	
Address:			City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:		E-mail:	
Current Weight: ____ lbs or ____ kgs Height: ____ inches or ____ cms			Allergies:		

B. INSURANCE INFORMATION

Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check one): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.			
Address:			City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:		
Provider Email:		Office Contact Name:		Phone:			

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration: <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____ NPI: _____	Dispensing Provider/Pharmacy: <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Mail Order <input type="checkbox"/> Other: _____ Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____ NPI: _____
--	--

E. PRODUCT INFORMATION

Request is for Aflibercept (Eylea): Dose: _____ Directions for Use: _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*).

Primary ICD Code: _____ Other ICD Code: _____ HCPCS Code: _____

G. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.

For All Requests: (Supporting documentation *must* be provided for review)

Note: Eylea is non-preferred. The preferred products are bevacizumab (Avastin) first followed by Byooviz. Avastin (C9257), and bevacizumab biosimilars do not require precertification for ophthalmic use.

Yes No Has the patient had prior therapy with Eylea (aflibercept) within the last 365 days?
 Yes No Has the patient had a trial and failure, intolerance, or contraindication to bevacizumab (Avastin)?
 Yes No Has the patient had a trial and failure, intolerance, or contraindication to Byooviz (ranibizumab-nuna)?
 Yes No Is the patient's visual acuity 20/50 or worse?

Please explain if there are any medical reason(s) that the patient cannot use bevacizumab (Avastin): _____

Please explain if there are any medical reason(s) that the patient cannot use Byooviz (ranibizumab-nuna): _____

Continued on next page



MEDICARE FORM

Eylea® (aflibercept) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:

FAX: 1-844-268-7263

PHONE: 1-866-503-0857 (TTY: 711)

For other lines of business:

Please use other form.

Note: Eylea is non-preferred. The preferred products are bevacizumab (Avastin) first followed by Byooviz. Avastin (C9257) and bevacizumab biosimilars do not require precertification for ophthalmic use.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

Please indicate the patient's BCVA prior to initiating treatment: ____/____ (e.g., 20/320)

Yes No Is this request for intravitreal injection of the eye? **If yes**, please indicate: OD (right eye) OS (left eye) OU (both eyes)

Yes No Will aflibercept (Eylea) be given in conjunction with another vascular endothelial growth factor inhibitor?

→ Yes No Will the medication be given in the same eye as aflibercept (Eylea)?

Yes No Does the patient have any of the following contraindications to aflibercept (Eylea)? (check all that apply)

→ Ocular infection Periocular infection Hypersensitivity Endophthalmitis

Please identify which documented diagnosis the patient is being treated for:

Diabetic Macular edema (including diabetic retinopathy in persons with macular edema)

Macular edema following retinal vein occlusion (RVO) (including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO))

Myopic choroidal neovascularization (mCNV) Neovascular (wet) (age related macular degeneration) AMD

For Continuation Requests:

Please indicate length of time on aflibercept (Eylea): _____

Please indicate the patient's current BCVA: ____/____ (e.g., 20/320)

Please choose the best response: BCVA has improved BCVA has remained the same

Small vision loss (defined as maximum of 3 lines or 15 letters lost on visual acuity exam)

None of the above

Yes No Has the patient had improvement in field vision?

Yes No Has the patient experienced a hypersensitivity reaction to aflibercept (Eylea)?

→ Please indicate which of the following hypersensitivity reactions the patient experienced:

anaphylactoid reactions pruritus rash severe anaphylactic reactions severe intraocular inflammation

urticaria Other: please explain: _____

Yes No Is this continuation request a result of the patient receiving samples of aflibercept (Eylea)?

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ Date: ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.